Biothera To Present Late-Breaking Data From Its Phase 2
EAGAN, Minn.--(BUSINESS WIRE)--Biothera will present today results on its investigational immunotherapy Imprime PGG® in combination with standard of care frontline chemotherapy and bevacizumab in patients with stage IV nonsquamous non-small cell lung cancer (NSCLC) at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.